Genomma Lab Internacional SAB de CV Class B released its earnings results on Apr 23, 2026. The company reported $0.028 earnings per share for the quarter, beating the consensus estimate of $0.026 by $0.002.

Is Genomma Lab Internacional SAB de CV Class B overvalued?

According to Wall Street analysts Genomma Lab Internacional SAB de CV Class B’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Genomma Lab Internacional SAB de CV Class B pay dividends?

Genomma Lab Internacional SAB de CV Class B pays a Quarterly dividend of $0.011 which represents an annual dividend yield of 4.48%. See more information on Genomma Lab Internacional SAB de CV Class B dividends here

What is Genomma Lab Internacional SAB de CV Class B’s EPS estimate?

Genomma Lab Internacional SAB de CV Class B’s EPS estimate is 0.03.

How many shares outstanding does Genomma Lab Internacional SAB de CV Class B have?

Genomma Lab Internacional SAB de CV Class B has 1,000,000,000 shares outstanding.

What happened to Genomma Lab Internacional SAB de CV Class B’s price movement after its last earnings report?

Genomma Lab Internacional SAB de CV Class B reported an EPS of $0.028 in its last earnings report, beating expectations of $0.026. Following the earnings report the stock price went down -7.103%.

Which hedge fund is a major shareholder of Genomma Lab Internacional SAB de CV Class B?

Currently, no hedge funds are holding shares in GNMLF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Genomma Lab Internacional SAB de CV Class B

Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, engages in the development, marketing, and sale of over-the-counter pharmaceutical and personal care products in Mexico and internationally. It provides skin care, health and wellness, hair care, pain relief, cough and cold, gastro, sexual health, antiperspirant deodorant, hand sanitizer, isotonic deink, and razor products, as well as analgesics, antifungals, and hemorrhoids. The company offers its products under the Cicatricure, Asepxia, Teatrical, Goicoechea, Sistema GB, Medicasp, Tío Nacho, Vanart, Novamil, Ultra Bengue, X-Ray, Tafirol, Alliviax, Bufferin, Next, XL-3, Genoprazol, QG5, Kaopectate, Proctan, Nikzon, Unesia, Silka Medic, lagicam, Suerox, Groomen, DiabetTX, and other brands. Genomma Lab Internacional, S.A.B. de C.V. was incorporated in 1996 and is based in Mexico City, Mexico.

Genomma Lab Internacional SAB de CV (GNMLF) Earnings & Revenues

Historic Earnings Reports

GNMLF Earnings Call

Q1 2026

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call presents a company facing significant challenges, including a decline in sales due to external economic conditions and hyperinflationary effects. However, the management's focus on cost-saving measures and strategic investments in growth initiatives highlights a proactive approach to overcoming these hurdles. The resilience of the EBITDA margin and strong historical growth provide a foundation for potential recovery.View all GNMLF earnings summaries